Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Japan Lifeline CoFRA:L8B -1.19%93 EV-to-EBITDA is 7.15 as of Aug. 22, 2026, which is 34% below its 10-year median of 10.81. GuruFocus rates FRA:L8B with a GF Score™ of 93/100 and a GF Value™ of €8.16. The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Japan Lifeline Co ranks better than 78.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Japan Lifeline Co's enterprise value is €559.1 Mil.
Japan Lifeline Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €78.2 Mil. Therefore, Japan Lifeline Co's EV-to-EBITDA for today is 7.15.
The historical rank and industry rank for Japan Lifeline Co's EV-to-EBITDA or its related term are showing as below:
FRA:L8B'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.63 Med: 10.81 Max: 31.57
Current: 7.35
During the past 13 years, the highest EV-to-EBITDA of Japan Lifeline Co was 31.57. The lowest was 5.63. And the median was 10.81.
FRA:L8B's EV-to-EBITDA is ranked better than 78.1% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.7
vs FRA:L8B: 7.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Japan Lifeline Co (FRA:L8B) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Japan Lifeline Co's PE Ratio (TTM) for today is calculated as:
Japan Lifeline Co's share price for today is €8.30.
Japan Lifeline Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.737.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Japan Lifeline Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Japan Lifeline Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Lifeline Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Japan Lifeline Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Japan Lifeline Co's EV-to-EBITDA falls into.
Japan Lifeline Co's current Enterprise Value is €559.1 Mil.
Japan Lifeline Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €78.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Lifeline Co (FRA:L8B) has a EV-to-EBITDA of 7.15 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Japan Lifeline Co. This is 34% below median its historical median of 10.81. Over the past decade, Japan Lifeline Co's EV-to-EBITDA has ranged from 5.63 to 31.57. According to the industry distribution chart, Japan Lifeline Co ranks #113 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 21.9%.
Is Japan Lifeline Co's EV-to-EBITDA too high?
Japan Lifeline Co's current EV-to-EBITDA of 7.15 is 34% below median its 10-year median of 10.81. Over the past 10 years, this metric has ranged from a low of 5.63 to a high of 31.57. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.70. Japan Lifeline Co's value of 7.15 is 51.4% below this industry median. Based on the distribution chart, Japan Lifeline Co ranks #113 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Japan Lifeline Co has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Japan Lifeline Co's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Japan Lifeline Co ranks #113 out of 516 companies for EV-to-EBITDA. This places Japan Lifeline Co in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.70. Japan Lifeline Co's value of 7.15 is 51.4% below this benchmark. Historically, Japan Lifeline Co's own EV-to-EBITDA has ranged from 5.63 to 31.57 over the past decade. While the company's 10-year median is 10.81 vs. the industry median of 14.70, Japan Lifeline Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.70, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Japan Lifeline Co's current EV-to-EBITDA of 7.15 is 51.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Japan Lifeline Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Lifeline Co's current EV-to-EBITDA is 7.15, which is 34% below median its own 10-year median of 10.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Lifeline Co stock overvalued right now?
Japan Lifeline Co (FRA:L8B) has a current EV-to-EBITDA of 7.15. The stock's GF Value™ is €8.16, compared to a current price of €8.30 — trading 1.7% above its estimated fair value. The current EV-to-EBITDA is 7.15, which is 34% below median its 10-year median of 10.81 and 51.4% below the Medical Devices & Instruments industry median of 14.70. Japan Lifeline Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Japan Lifeline Co (FRA:L8B), the current EV-to-EBITDA is 7.15 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Lifeline Co (FRA:L8B) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Lifeline Co stock appears to be overvalued.
The current stock price of €8.30 is trading 1.7% above its estimated GF Value™ of €8.16.
Key valuation signals for FRA:L8B:
EV-to-EBITDA: 7.15 (34% below median its 10-year median of 10.81)
GF Value™: €8.16 vs. price of €8.30 (1.7% above fair value)
Industry Position: 51.4% below the Medical Devices & Instruments median (#113 of 516)
No single metric tells the full story. See the FRA:L8B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Lifeline Co Ltd is a medical device company operating in Japan. It is engaged in the trading and manufacturing of medical devices specialized in the cardiovascular field. The company offers medical devices mainly for the treatment of cardiac and vascular diseases. It focuses on providing implantable devices to treat arrhythmias; disposable catheter devices with electrodes for diagnosis and treatment of arrhythmias; prosthetic devices to replace blood vessels and heart valves that lost their functions; and devices for intravascular treatment of cardiac infarction, arterial occlusions of the lower extremities and congenital cardiac diseases.
93GF Score
Get the complete analysis for FRA:L8B
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L8B has been successfully added to your 
